Sarepta Therapeutics Long Term Debt

As of the most recent data (March 2026), SRPT shows a long-term debt of $1.2B. That compares with $1.3B in the prior-year period — down 8.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SRPT's long-term debt is now $1.2B (was $1.3B) — a 8.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Sarepta Therapeutics is outperforming or lagging.

Tracking SRPT's long-term debt over time shows whether Sarepta Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.2B That compares with $1.3B in the prior-year period — down 8.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Sarepta Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.2B) with ownership activity and broader fundamentals.

Sarepta Therapeutics's long-term debt is $1.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.